Cargando…

Development of Novel Tetrapyrrole Structure Photosensitizers for Cancer Photodynamic Therapy

The effectiveness of photodynamic therapy (PDT) is based on the triad effects of photosensitizer (PS), molecular oxygen and visible light on malignant tumors. Such complex induces a multifactorial manner including reactive-oxygen-species-mediated damage and the killing of cells, vasculature damage o...

Descripción completa

Detalles Bibliográficos
Autores principales: Plekhova, Natalia, Shevchenko, Olga, Korshunova, Oksana, Stepanyugina, Aleksandra, Tananaev, Ivan, Apanasevich, Vladimir
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8868602/
https://www.ncbi.nlm.nih.gov/pubmed/35200435
http://dx.doi.org/10.3390/bioengineering9020082
_version_ 1784656306799378432
author Plekhova, Natalia
Shevchenko, Olga
Korshunova, Oksana
Stepanyugina, Aleksandra
Tananaev, Ivan
Apanasevich, Vladimir
author_facet Plekhova, Natalia
Shevchenko, Olga
Korshunova, Oksana
Stepanyugina, Aleksandra
Tananaev, Ivan
Apanasevich, Vladimir
author_sort Plekhova, Natalia
collection PubMed
description The effectiveness of photodynamic therapy (PDT) is based on the triad effects of photosensitizer (PS), molecular oxygen and visible light on malignant tumors. Such complex induces a multifactorial manner including reactive-oxygen-species-mediated damage and the killing of cells, vasculature damage of the tumor, and activation of the organism immunity. The effectiveness of PDT depends on the properties of photosensitizing drugs, their selectivity, enhanced photoproduction of reactive particles, absorption in the near infrared spectrum, and drug delivery strategies. Photosensitizers of the tetrapyrrole structure (porphyrins) are widely used in PDT because of their unique diagnostic and therapeutic functions. Nevertheless, the clinical use of the first-generation PS (sodium porfimer and hematoporphyrins) revealed difficulties, such as long-term skin photosensitivity, insufficient penetration into deep-seated tumors and incorrect localization to it. The second generation is based on different approaches of the synthesis and conjugation of porphyrin PS with biomolecules, which made it possible to approach the targeted PDT of tumors. Despite the fact that the development of the second-generation PS started about 30 years ago, these technologies are still in demand and are in intensive development, especially in the direction of improving the process of optimization split linkers responsive to input. Bioconjugation and encapsulation by targeting molecules are among the main strategies for developing of the PS synthesis. A targeted drug delivery system with the effect of increased permeability and retention by tumor cells is one of the ultimate goals of the synthesis of second-generation PS. This review presents porphyrin PS of various generations, discusses factors affecting cellular biodistribution and uptake, and indicates their role as diagnostic and therapeutic (theranostic) agents. New complexes based on porphyrin PS for photoimmunotherapy are presented, where specific antibodies are used that are chemically bound to PS, absorbing light from the near infrared part of the spectrum. Additionally, a two-photon photodynamic approach using third-generation photosensitizers for the treatment of tumors is discussed, which indicates the prospects for the further development of a promising method antitumor PDT.
format Online
Article
Text
id pubmed-8868602
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-88686022022-02-25 Development of Novel Tetrapyrrole Structure Photosensitizers for Cancer Photodynamic Therapy Plekhova, Natalia Shevchenko, Olga Korshunova, Oksana Stepanyugina, Aleksandra Tananaev, Ivan Apanasevich, Vladimir Bioengineering (Basel) Review The effectiveness of photodynamic therapy (PDT) is based on the triad effects of photosensitizer (PS), molecular oxygen and visible light on malignant tumors. Such complex induces a multifactorial manner including reactive-oxygen-species-mediated damage and the killing of cells, vasculature damage of the tumor, and activation of the organism immunity. The effectiveness of PDT depends on the properties of photosensitizing drugs, their selectivity, enhanced photoproduction of reactive particles, absorption in the near infrared spectrum, and drug delivery strategies. Photosensitizers of the tetrapyrrole structure (porphyrins) are widely used in PDT because of their unique diagnostic and therapeutic functions. Nevertheless, the clinical use of the first-generation PS (sodium porfimer and hematoporphyrins) revealed difficulties, such as long-term skin photosensitivity, insufficient penetration into deep-seated tumors and incorrect localization to it. The second generation is based on different approaches of the synthesis and conjugation of porphyrin PS with biomolecules, which made it possible to approach the targeted PDT of tumors. Despite the fact that the development of the second-generation PS started about 30 years ago, these technologies are still in demand and are in intensive development, especially in the direction of improving the process of optimization split linkers responsive to input. Bioconjugation and encapsulation by targeting molecules are among the main strategies for developing of the PS synthesis. A targeted drug delivery system with the effect of increased permeability and retention by tumor cells is one of the ultimate goals of the synthesis of second-generation PS. This review presents porphyrin PS of various generations, discusses factors affecting cellular biodistribution and uptake, and indicates their role as diagnostic and therapeutic (theranostic) agents. New complexes based on porphyrin PS for photoimmunotherapy are presented, where specific antibodies are used that are chemically bound to PS, absorbing light from the near infrared part of the spectrum. Additionally, a two-photon photodynamic approach using third-generation photosensitizers for the treatment of tumors is discussed, which indicates the prospects for the further development of a promising method antitumor PDT. MDPI 2022-02-19 /pmc/articles/PMC8868602/ /pubmed/35200435 http://dx.doi.org/10.3390/bioengineering9020082 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Plekhova, Natalia
Shevchenko, Olga
Korshunova, Oksana
Stepanyugina, Aleksandra
Tananaev, Ivan
Apanasevich, Vladimir
Development of Novel Tetrapyrrole Structure Photosensitizers for Cancer Photodynamic Therapy
title Development of Novel Tetrapyrrole Structure Photosensitizers for Cancer Photodynamic Therapy
title_full Development of Novel Tetrapyrrole Structure Photosensitizers for Cancer Photodynamic Therapy
title_fullStr Development of Novel Tetrapyrrole Structure Photosensitizers for Cancer Photodynamic Therapy
title_full_unstemmed Development of Novel Tetrapyrrole Structure Photosensitizers for Cancer Photodynamic Therapy
title_short Development of Novel Tetrapyrrole Structure Photosensitizers for Cancer Photodynamic Therapy
title_sort development of novel tetrapyrrole structure photosensitizers for cancer photodynamic therapy
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8868602/
https://www.ncbi.nlm.nih.gov/pubmed/35200435
http://dx.doi.org/10.3390/bioengineering9020082
work_keys_str_mv AT plekhovanatalia developmentofnoveltetrapyrrolestructurephotosensitizersforcancerphotodynamictherapy
AT shevchenkoolga developmentofnoveltetrapyrrolestructurephotosensitizersforcancerphotodynamictherapy
AT korshunovaoksana developmentofnoveltetrapyrrolestructurephotosensitizersforcancerphotodynamictherapy
AT stepanyuginaaleksandra developmentofnoveltetrapyrrolestructurephotosensitizersforcancerphotodynamictherapy
AT tananaevivan developmentofnoveltetrapyrrolestructurephotosensitizersforcancerphotodynamictherapy
AT apanasevichvladimir developmentofnoveltetrapyrrolestructurephotosensitizersforcancerphotodynamictherapy